News

November 20, 2017

Biologics Industry Must Embrace Innovative Manufacturing Strategies to Keep Pace with a Changing Marketplace

BOSTON – Nov. 20, 2017 – Innovative biologics manufacturing is reducing production costs while fundamentally changing how life-saving drugs are produced, according to a recently published White Paper by the Tufts Center for the Study of Drug Development.

In October 2015, Tufts CSDD hosted a roundtable discussion moderated by Abdullah Baaj, MD, PharmD, Parrish Galliher, MS, and Kenneth Kaitin, PhD, which included senior managers from biologics development companies and officials from the U.S. Department of Defense and HHS’ Assistant Secretary for Preparedness and Response. Participants shared their thoughts, experiences and insights on new strategies for biologics manufacturing, an area of rapid change.

Findings have been published in a White Paper, entitled “Manufacturing Strategy for Diverse Biologic Pipelines of the Future.”

According to Dr. Baaj, Founder and CEO of Boston Oncology and lead author of the White Paper, “There is an urgent need for biologics developers to share technology and collaborate to develop the manufacturing platforms, standards and practices required to meet the demands of the future. The global impact of the shift in innovative biologics manufacturing could be groundbreaking.”

White Paper highlights include:

  •  Biologics makers are increasingly turning to manufacturing as a way to contain costs while increasing product quality and adapting to market demands.
  •  Continuous and real-time manufacturing can improve the government’s emergency preparedness to respond to real crises.  
  •  Globalization and manufacturing decentralization have created significant investment opportunities for biologics manufacturing in emerging and developing markets.

To download a copy of the White Paper, visit http://csdd.tufts.edu/reports/white_papers.

ABOUT THE TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT

The Tufts Center for the Study of Drug Development (http://csdd.tufts.edu) at Tufts University provides strategic information to help drug developers, regulators, and policy makers improve the efficiency and productivity of pharmaceutical R&D. Tufts CSDD, based in Boston, conducts a wide range of in-depth analyses on pharmaceutical issues, hosts symposia, workshops, and public forums, and publishes Tufts CSDD Impact Reports, a bi-monthly newsletter providing analysis and insight into critical drug development issues.

-end-

Contact:

Dr. Abdullah Baaj

Founder and CEO, Boston Oncology, Inc.

abaaj@bostononcology.com

ABOUT RESEARCH COURSES & FORUMS LIBRARY & BIBLIOGRAPHY REPORTS SPONSORED RESEARCH NEWS